Arthroscopic Debridement Versus Autologous Cytokine Rich Serum for the Treatment of Lateral Epicondylitis — DA-SARC  

Epicondylitis, Lateral Clinical Trial

Official title: Randomized Clinical Trial Comparing Arthroscopic Debridement Versus Autologous Cytokine Rich Serum for the Treatment of Lateral Epicondylitis

Status Recruiting

Clinical Trial Summary

This study aims to compare arthroscopic resection (surgical intervention) versus infiltration of cytokine rich serum (CRS) (proteins derived from the patient's own blood) for the treatment of lateral epicondylitis (LE).

Clinical Trial Description

Lateral epicondylitis (LE) is a common debilitating condition that affects the extensor muscles of the forearm at its junction with the lateral humeral epicondyle. This pathology is commonly treated by a surgical intervention. However, advances in research have allowed the discovery of new and less invasive techniques for its treatment, for example the infiltration of cytokine rich serum.

The aim of the study is to compare the common treatment of this pathology, arthroscopic resection (surgical intervention) with a new technique, infiltration of cytokine rich serum (CRS) (proteins derived from the patient's own blood) with respect to medium and long-term pain reduction.

The study will include a total of 86 patients. Patients will be included by randomization into two groups:

• GROUP 1: 43 patients will be treated with 2 infiltrations of cytokine rich serum.

• GROUP 2: 43 patients will be treated by a regular surgical treatment consisting of arthroscopic resection.

The main objective of this study is to evaluate the efficacy of CRS as compared to arthroscopic resection in reducing pain in the medium term (6 months) in patients with chronic lateral epicondylitis. ;

Related Conditions & MeSH terms

• Epicondylitis, Lateral
• Tennis Elbow

• NCT number: NCT04194710
• Study type: Interventional
• Source: Corporacion Parc Tauli
• Contact: Laia Martínez Carreres, PhD
• Phone: 937231010
• Email: lmartinezc@tauli.cat
• Status: Recruiting
• Phase: N/A
• Start date: December 22, 2020
• Completion date: December 1, 2023